Physician

Hakan Kaya, M.D.

According to 2025 Medicare claims, Hakan Kaya, M.D. (NPI: 1255320974) practices medical oncology in the Spokane-Spokane Valley, WA market, with the plurality of this provider's patient population coming from Spokane, WA. This provider's primary affiliated billing organization is CANCER CARE NORTHWEST CENTERS P S (NPI: 1922072081; TIN: 911007627) and primary practice location at 99202-1311. Kaya is affiliated with the Kootenai Accountable Care, LLC (ACO ID: A3621) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Kaya's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 454 traditional Medicare patients, billed 125,655 HCPCS/CPT codes, and received $3,341,065 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,339 prescription claims across 170 beneficiaries totaling $5,684,720 in drug costs, led by Brukinsa (Zanubrutinib). 2023 DME data shows 51 claims. Open Payments data shows 330 records totaling $426,032. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,617,185 to $3,341,065. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,431,408 to $5,684,720. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.8M$3.6M2015 Medicare payment: $1,617,185 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,654,808 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,363,338 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,403,901 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,929,481 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,626,375 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,823,788 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,265,564 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $3,226,487 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,341,065 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201550074,960$1,617,185
201649381,054$1,654,808
201743461,548$1,363,338
2018588133,095$2,403,901
2019585144,206$2,929,481
2020630185,794$3,626,375
202155997,461$2,823,788
202249094,181$2,265,564
2023575138,018$3,226,487
2024454125,655$3,341,065

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$3.3M$6.6M2015 Drug cost: $1,431,408 (USD; Tot_Drug_Cst)2016 Drug cost: $2,302,717 (USD; Tot_Drug_Cst)2017 Drug cost: $3,045,447 (USD; Tot_Drug_Cst)2018 Drug cost: $3,671,608 (USD; Tot_Drug_Cst)2019 Drug cost: $4,767,677 (USD; Tot_Drug_Cst)2020 Drug cost: $5,593,225 (USD; Tot_Drug_Cst)2021 Drug cost: $6,648,896 (USD; Tot_Drug_Cst)2022 Drug cost: $6,412,882 (USD; Tot_Drug_Cst)2023 Drug cost: $5,375,236 (USD; Tot_Drug_Cst)2024 Drug cost: $5,684,720 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151171,231$1,431,408
20161251,316$2,302,717
20171171,362$3,045,447
20181261,278$3,671,608
20191421,427$4,767,677
20201581,541$5,593,225
20211541,781$6,648,896
20221571,596$6,412,882
20231821,527$5,375,236
20241701,339$5,684,720

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$1.5K$3.0K2015 Medicare payment: $1,936 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $1,185 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $1,662 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $38 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $1,006 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $3,002 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R24$1,936
2016N/R24$1,185
2017N/R51$1,662
2018N/R12$38
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/R24$1,006
2023N/R51$3,002
2024N/RN/RN/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more202375$94
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more171252$67
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's164301$12
36415Insertion of needle into vein for collection of blood sample247936$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count253973$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
BrukinsaZanubrutinib872,610$1,219,323
PomalystPomalidomide501,400$1,160,877
RevlimidLenalidomide471,316$872,040
LenalidomideLenalidomide411,148$569,867
NinlaroIxazomib Citrate22616$298,475

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.324$420,032Takeda Pharmaceuticals U.S.A., Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.6$6,000Genentech, Inc.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Hakan Kaya, M.D.?

Tedicare shows public-source Medicare data for Hakan Kaya, M.D. (NPI 1255320974), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hakan Kaya, M.D. have ACO affiliation data?

Hakan Kaya, M.D. is shown with ACO affiliation data for Kootenai Accountable Care, LLC (MSSP, ACO ID A3621) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Hakan Kaya, M.D.?

Hakan Kaya, M.D. is linked to CANCER CARE NORTHWEST CENTERS P S (billing NPI 1922072081) in the available physician profile data.

Does Hakan Kaya, M.D. have Open Payments data?

Hakan Kaya, M.D. has 330 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.